AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26925955 — intervention group
Group type: EXPERIMENTAL
Intervention: VR balance training program using the CAREN system for 6 weeks, 2 sessions per week, 30 minutes each session.
Number of subjects: 32
Study 26925955 — intervention group
Group type: COMPARATOR
Intervention: Conventional balance exercise group for 6 weeks, 2 sessions per week, 30 minutes each session.
Number of subjects: 32
Study 25281300 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based breastfeeding support
Number of subjects: 450
Study 25281300 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based breastfeeding support plus access to a community-based breastfeeding drop-in centre
Number of subjects: 450
Study 25281300 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 450
Study 22301931 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 33
Study 22301931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19930762 — intervention group
Group type: EXPERIMENTAL
Intervention: HFrD (hypercaloric diet enriched with fructose, 3.5 g fructose/kg fat‐free mass per day, +35% energy intake)
Number of subjects: 11
Study 19930762 — intervention group
Group type: EXPERIMENTAL
Intervention: HGlcD (hypercaloric diet enriched with glucose, 3.5 g glucose/kg fat‐free mass per day, +35% energy intake)
Number of subjects: 11
Study 19930762 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance control diet
Number of subjects: 11
Study 17350525 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% (19-mL bolus) followed by levobupivacaine 0.1% infusion
Number of subjects: 38
Study 17350525 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 microg (19-mL bolus) followed by levobupivacaine 0.05% with fentanyl 4 microg/mL infusion
Number of subjects: 38
Study 17350525 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 microg (19-mL bolus) followed by levobupivacaine 0.05% with clonidine 3 microg/mL infusion
Number of subjects: 38
Study 15716984 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control program
Number of subjects: 0
Study 11929640 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 987
Study 11929640 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation progestins (levonorgestrel or norgestimate)
Number of subjects: 987
Study 11929640 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation progestins (desogestrel or gestodene)
Number of subjects: 987
Study 11929640 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives with 20 microg estrogen
Number of subjects: 987
Study 11929640 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives with 50 microg estrogen
Number of subjects: 987
Study 11929640 — intervention group
Group type: EXPERIMENTAL
Intervention: Third/second-generation OCs
Number of subjects: 987
Study 11229219 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate (660 mg) for 6 weeks (Group‐‐IIB)
Number of subjects: 50
Study 11229219 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks (Group‐‐IIA)
Number of subjects: 50
Study 11229219 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (Group‐‐I)
Number of subjects: 50
Study 7649958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg
Number of subjects: 17
Study 7649958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg
Number of subjects: 17
Study 7649958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.9 mg/kg
Number of subjects: 17
Study 7649958 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) (all dosages)
Number of subjects: 17
Study 2627869 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Learning Intervention (SLI) with role modeling
Number of subjects: 34
Study 2627869 — intervention group
Group type: COMPARATOR
Intervention: Traditional diabetes instruction (Control)
Number of subjects: 34
Study 1091138 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete dietary supplement consisting of a beef serum hydrolysate, a glucose polymer, and medium‐chain triglycerides
Number of subjects: 15
Study 1091138 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who did not receive the supplement)
Number of subjects: 15
Study 31328599 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received a training course comprising of 20 hours over 5 weeks.
Number of subjects: 28
Study 31328599 — intervention group
Group type: COMPARATOR
Intervention: Conventional training group.
Number of subjects: 28
Study 28549048 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable underpads
Number of subjects: 462
Study 28549048 — intervention group
Group type: COMPARATOR
Intervention: Reusable underpads
Number of subjects: 462
Study 26786080 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 20
Study 26786080 — intervention group
Group type: COMPARATOR
Intervention: Classic Sensory Re-education (Control)
Number of subjects: 20
Study 24667751 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (200 kcal/250 ml)
Number of subjects: 15
Study 24667751 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (200 kcal/250 ml)
Number of subjects: 15
Study 24667751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup (HFCS) (200 kcal/250 ml)
Number of subjects: 15
Study 24667751 — intervention group
Group type: EXPERIMENTAL
Intervention: HFCS (200 kcal/250 ml)
Number of subjects: 15
Study 24667751 — intervention group
Group type: COMPARATOR
Intervention: Sucralose (non-caloric control)
Number of subjects: 15
Study 21900886 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 35
Study 21900886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19164774 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month high-intensity exercise program
Number of subjects: 49
Study 19164774 — intervention group
Group type: COMPARATOR
Intervention: Inactive control period
Number of subjects: 49
Study 17878516 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA microarrays and tissue microarrays for biomarker validation
Number of subjects: 0
Study 15277595 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing visco-elastic model foods of different hardness
Number of subjects: 67
Study 11354406 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt with Delta valves
Number of subjects: 12
Study 11354406 — intervention group
Group type: COMPARATOR
Intervention: Shunt with Hakim shunts
Number of subjects: 12
Study 9164415 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (200 mg every 8 hours, 300 mg every 8 hours, 400 mg every 8 hours)
Number of subjects: 8
Study 9164415 — intervention group
Group type: COMPARATOR
Intervention: Control group (300 mg every 8 hours)
Number of subjects: 8
Study 9164415 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (all doses)
Number of subjects: 8
Study 7965930 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, structured pain management program (three-session program)
Number of subjects: 26
Study 7965930 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no specific intervention mentioned)
Number of subjects: 26
Study 2885638 — intervention group
Group type: COMPARATOR
Intervention: Whole marrow (group A)
Number of subjects: 71
Study 2885638 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD4‐CD5‐CD8, group B)
Number of subjects: 71
Study 2885638 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrow depleted of T cells by treatment with monoclonal antibodies (anti CD2‐CD5‐CD7, group C)
Number of subjects: 71
Study 31994173 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia module
Number of subjects: 75
Study 31994173 — intervention group
Group type: COMPARATOR
Intervention: Written information
Number of subjects: 75
Study 29412335 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy (20 weekly sessions, 90 min/session)
Number of subjects: 56
Study 29412335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study 28257246 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 76
Study 28257246 — intervention group
Group type: COMPARATOR
Intervention: Control program
Number of subjects: 76
Study 26394351 — intervention group
Group type: EXPERIMENTAL
Intervention: Autograft
Number of subjects: 15
Study 26394351 — intervention group
Group type: COMPARATOR
Intervention: Allograft
Number of subjects: 15
Study 23673096 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 40
Study 23673096 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypervolemic hemodilution (AHH)
Number of subjects: 40
Study 21261705 — intervention group
Group type: EXPERIMENTAL
Intervention: Music exposure (Music for Dreaming, Sound Impressions, Pty. Ltd.) at 50‐55 decibel A
Number of subjects: 20
Study 21261705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music exposure)
Number of subjects: 20
Study 18292426 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% xenon
Number of subjects: 75
Study 18292426 — intervention group
Group type: COMPARATOR
Intervention: 70% nitrous oxide
Number of subjects: 75
Study 16551778 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomographic Angiography (CTA)
Number of subjects: 116
Study 12666865 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical tube drain before primary closure
Number of subjects: 13
Study 12666865 — intervention group
Group type: COMPARATOR
Intervention: Primary closure alone (no drain)
Number of subjects: 13
Study 10881243 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation (KS+T)
Number of subjects: 20
Study 10881243 — intervention group
Group type: EXPERIMENTAL
Intervention: No testosterone supplementation (KS-T)
Number of subjects: 20
Study 10881243 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 20
Study 9547134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 400
Study 9547134 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20-60 mg/day)
Number of subjects: 400
Study 9547134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 400
Study 8507759 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin and doxycycline for 4 weeks
Number of subjects: 0
Study 8507759 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole for 6 months
Number of subjects: 0
Study 8507759 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline for 6 weeks
Number of subjects: 0
Study 8507759 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptomycin for 2 or 3 weeks with doxycycline for 6 weeks
Number of subjects: 0
Study 8507759 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin with doxycycline for 6 weeks
Number of subjects: 0
Study 8507759 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (single-agent therapy)
Number of subjects: 0
Study 3324441 — intervention group
Group type: EXPERIMENTAL
Intervention: SolcoUrovac
Number of subjects: 400
Study 3324441 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin or another appropriate antibiotic
Number of subjects: 400
Study 29913392 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 30
Study 29913392 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal analgesia
Number of subjects: 30
Study 27764102 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) administered once per month from September to November.
Number of subjects: 780000
Study 24951234 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill workstation
Number of subjects: 15
Study 24951234 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical trainer workstation
Number of subjects: 15
Study 24951234 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer workstation
Number of subjects: 15
Study 24951234 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing workstation
Number of subjects: 15
Study 24951234 — intervention group
Group type: COMPARATOR
Intervention: Sitting workstation
Number of subjects: 15
Study 22956016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (BSCPB) with 20 mL of 0.525% ropivacaine
Number of subjects: 97
Study 22956016 — intervention group
Group type: EXPERIMENTAL
Intervention: Local wound infiltration (LWI) with 20 mL of 0.525% ropivacaine
Number of subjects: 97
Study 22956016 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (Control group)
Number of subjects: 97
Study 20816190 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to community violence (ECV)
Number of subjects: 397
Study 18484388 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led programme
Number of subjects: 0
Study 18484388 — intervention group
Group type: COMPARATOR
Intervention: Self-directed learning module
Number of subjects: 0
Study 18484388 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5-day workshops
Number of subjects: 0
Study 18484388 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based teaching modules
Number of subjects: 0
Study 15728422 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intensive pool exercise therapy (twice a week for 12 weeks)
Number of subjects: 46
Study 15728422 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued previous activities)
Number of subjects: 46
Study 11322867 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (0.2 microgram/kg bolus followed by 0.01 microgram/kg/min continuous infusion)
Number of subjects: 0
Study 11322867 — intervention group
Group type: COMPARATOR
Intervention: iv. nitroglycerine
Number of subjects: 0
Study 9675835 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable gastroscope (G-F100)
Number of subjects: 40
Study 9675835 — intervention group
Group type: COMPARATOR
Intervention: Standard gastroscope (GIF-Q 30)
Number of subjects: 40
Study 9675835 — intervention group
Group type: COMPARATOR
Intervention: Both gastroscopes
Number of subjects: 40
Study 8002639 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 at 15 mg/m2
Number of subjects: 25
Study 8002639 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 at 20 mg/m2
Number of subjects: 25
Study 8002639 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 at 20 mg/m2 or higher doses
Number of subjects: 25
Study 8002639 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 at 25 mg/m2
Number of subjects: 25
Study 8002639 — intervention group
Group type: EXPERIMENTAL
Intervention: KW-2307 combined with cisplatin (CDDP) at 80 mg/m2
Number of subjects: 25
Study 2510523 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatekeeper plan
Number of subjects: 0
Study 2510523 — intervention group
Group type: COMPARATOR
Intervention: Plan without a gatekeeper
Number of subjects: 0
Study 818046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Ara A
Number of subjects: 0
Study 818046 — intervention group
Group type: COMPARATOR
Intervention: Topical antiviral agents (IDU)
Number of subjects: 0
Study 6903906 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, informative in-home teaching concerning infant behavior
Number of subjects: 30
Study 6903906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured teaching)
Number of subjects: 30
Study 30712743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises performed three times a week for 12 weeks
Number of subjects: 50
Study 30712743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study 28222801 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 6 × 10^6 hADSCs per 3 ml suspended in phosphate buffer saline
Number of subjects: 18
Study 28222801 — intervention group
Group type: COMPARATOR
Intervention: Injection of 3 ml phosphate buffer saline (placebo)
Number of subjects: 18
Study 24771618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 2327
Study 22884184 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splint (during the day) + routine care (exercises and advice for 8 weeks)
Number of subjects: 40
Study 22884184 — intervention group
Group type: COMPARATOR
Intervention: Routine care (exercises and advice for 8 weeks)
Number of subjects: 40
Study 20000291 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 25
Study 20000291 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-flap LASIK
Number of subjects: 25
Study 20000291 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PRK and Thin-flap LASIK
Number of subjects: 25
Study 17314444 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical garlic gel with betamethasone cream 0.1%
Number of subjects: 40
Study 17314444 — intervention group
Group type: COMPARATOR
Intervention: Placebo with betamethasone cream 0.1%
Number of subjects: 40
Study 15153582 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials in podiatric medicine
Number of subjects: 0
Study 11161545 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (12 U/dose) for 5 h
Number of subjects: 30
Study 11161545 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment (12 U/dose) for 5 days
Number of subjects: 30
Study 11161545 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9806287 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART1 (protein-free medium)
Number of subjects: 93
Study 9806287 — intervention group
Group type: COMPARATOR
Intervention: FertiCult (HSA containing medium)
Number of subjects: 93
Study 7983614 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of extrinsic need for job security (nSec)
Number of subjects: 383
Study 7983614 — intervention group
Group type: COMPARATOR
Intervention: Absence of extrinsic need for job security (nSec)
Number of subjects: 383
Study 7983614 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of extrinsic need for job security (nSec) in subjects over 50 years old
Number of subjects: 383
Study 7983614 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlational association between nAch and LOC
Number of subjects: 383
Study 3056498 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 1 mg (group A)
Number of subjects: 60
Study 3056498 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone acetate 0.5 mg (group B)
Number of subjects: 60
Study 3056498 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 5 mg (group C)
Number of subjects: 60
Study 3056498 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 2.5 mg (group D)
Number of subjects: 60
Study 31226957 — intervention group
Group type: EXPERIMENTAL
Intervention: Andilaye intervention
Number of subjects: 50
Study 31226957 — intervention group
Group type: COMPARATOR
Intervention: Standard of care sanitation and hygiene programming (CLTSH)
Number of subjects: 50
Study 28668855 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetium® lozenge (slow-release L-Cysteine)
Number of subjects: 1998
Study 28668855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1998
Study 26964163 — intervention group
Group type: EXPERIMENTAL
Intervention: Hooking therapy followed by safflower injection, once every 6 to 7 days, under local anesthesia. If efficacy was not satisfactory, a second treatment was given.
Number of subjects: 60
Study 26964163 — intervention group
Group type: COMPARATOR
Intervention: Safflower injection applied to three points of lumbar region, once a day for 2 sessions (7 treatments per session).
Number of subjects: 60
Study 24136585 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 271
Study 21259343 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A (250 U Dysport)
Number of subjects: 27
Study 21259343 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐B (2500 U Neurobloc)
Number of subjects: 27
Study 19404150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative normothermia (36 degrees C‐37 degrees C)
Number of subjects: 1000
Study 19404150 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative hypothermia (32.5 degrees C‐33.5 degrees C)
Number of subjects: 1000
Study 16381068 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.19 mg/kg oral)
Number of subjects: 48
Study 16381068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15259328 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuo-verbal test
Number of subjects: 50
Study 15259328 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal test
Number of subjects: 50
Study 15259328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 11479462 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose recombinant tPA (8 mg bolus followed by 42 mg infusion)
Number of subjects: 400
Study 11479462 — intervention group
Group type: COMPARATOR
Intervention: Urokinase (1.5 million units as a 30-minute infusion)
Number of subjects: 400
Study 11479462 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose recombinant tPA
Number of subjects: 400
Study 11479462 — intervention group
Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 400
Study 11479462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 400
Study 9725479 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (25 mg)
Number of subjects: 24
Study 9725479 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg)
Number of subjects: 24
Study 9725479 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (25 mg) and Ibuprofen (200 mg) in association
Number of subjects: 24
Study 8306744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 10
Study 8306744 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (Control)
Number of subjects: 10
Study 2686494 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol, 2 mg/min to a maximum of 300 mg
Number of subjects: 91